Original Research
Sunday, October 13, 2024
12:45 PM–02:15 PM
Abstract
Introduction:
Comorbidity could influence cancer diagnosis, treatment, prognosis, or survival. Although comorbidity burden in kidney cancer patients is high, limited evidence exists on the longitudinal patterns of individual comorbidity prevalence and its impact on overall survival among kidney cancer patients, particularly in Asian populations.
Research Question or Hypothesis:
What is the burden of comorbidities in kidney cancer patients and its impact on overall survival?
Study Design: Longitudinal observational study
Methods:
We included adults diagnosed with kidney cancer (2010-2021) using the Korean Nationwide Health Insurance database. Comorbidities assessed were any one of nineteen medical conditions, diagnosed within one year prior to cancer diagnosis. We calculated incidence and age-standardized incidence rate of kidney cancer, prevalence of individual medical conditions as single or multiple comorbidities, and overall survival probability of kidney cancer patients over a 12-year period. We estimated the odds ratio of having individual and multiple comorbidities with age and sex as independent covariates and adjusted for other comorbidities. Kaplan-Meier curves were used for overall survival at different times up to 5 years of follow-up.
Results:
Among kidney cancer patients (N=42,740), 68.7% were men, and median (interquartile range) age was 59 (49-68) years. Approximately 76% of patients had at least one comorbidity at the time of cancer diagnosis. Overall, hypertension (51.3%), dyslipidemia (40.2%), mild liver disease (27.4%), diabetes (25.1%), and peptic ulcer disease (18.9%) were the most prevalent comorbidities. The proportion of patients having three or more comorbidities continuously increased from 2010 (29.4%) to 2021 (44.9%). Having more comorbidities was associated with a lower probability of overall survival.
Conclusion:
Proportion of patients with multiple conditions is high and has been increased over time. Although survival probability increased over time, it was attenuated by having more comorbidities. Our data emphasizes the importance of comprehensive management for both cancer and comorbid conditions in kidney cancer patients.
Presenting Author
Sukhyang Lee PharmD, PhDAjou University
Authors
Eunjung Choo MS
Ajou University
Benjamin Chung MD
Stanford Medicine
Minji Jung PharmD, PhD
University of California San Francisco
Marvin Langston PhD
Stanford University